Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
Epistemonikos ID: 269619a727ef61b51fe41b647750b876c57a4ae9
First added on: May 07, 2024